drugset / Trial / NCT00091117

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

NCT00091117 ↗

Phase 1 Completed 80 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. This phase I trial is studying the side effects and best dose of bortezomib in treating patients with advanced cancer and liver dysfunction.

Timeline

Start
2004-07
Primary completion
2013-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 0.5 mg/m2 Intravenous
Subject Bortezomib Small molecule 0.7 mg/m2 Intravenous
Subject Bortezomib Small molecule 1 mg/m2 Intravenous
Subject Bortezomib Small molecule 1.3 mg/m2 Intravenous

Indications